Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma

Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma have?

Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma has 69 citations in the OpenAlex counts ScholarIQ stores.

When was Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma published?

Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma has 2004 year in the ScholarIQ index.

What is the open-access status of Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma?

Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma has bronze oa status in the ScholarIQ index.

What is the DOI of Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma?

The DOI for Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma is on the source record.

What is the PMID of Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma?

The PMID for Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma is on the source record.

What is the OpenAlex record for Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma?

The OpenAlex for Concomitant versus sequential administration of epirubicin and paclitaxel as first‐line therapy in metastatic breast carcinoma is on the source record.